Pls. find enclosed herewith Investor Presentation.

17th August, 2026 To, To, The General Manager The Manager, Department of Corporate Services Listing Department, BSE Ltd. National Stock Exchange of India Ltd. Phiroze Jeejeebhoy Towers, “Exchange Plaza”, C-1, Block G, Dalal Street, Bandra-Kurla Complex, Mumbai – 400 001. Bandra (E), Mumbai – 400 051. Ref.: Scrip Code No. : 540701 (Equity) Ref. : (i) Symbol – DCAL : 975834, 976560, 977467 and 977859 (Debt) (ii) Series – EQ SUB: INVESTORS PRESENTATION ON UN-AUDITED FINANCIAL RESULT – REGULATIONS: 30 and 51 Dear Sir, Pursuant to Regulations 30 and 51 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, pls. find enclosed herewith Presentation on Un- Audited financial result for the quarter ended 30th June, 2026 to be made to Analyst and Investors. The aforesaid presentation is also being hosted on the website of the Company, www.imdcal.com in accordance with the Regulations 46 and 62 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015. Kindly take the same on your record. Yours faithfully, For, Dishman Carbogen Amcis Limited Shrima Dave Company Secretary Encl.: As above Investor Presentation Q1FY27 Quater ended June 30, 2026 This presentation and the following discussion may contain “forward looking statements” by Dishman Carbogen Amcis Limited (‘Dishman’ or the ‘Company’) that are not historical in nature. These forward-looking statements, which may include statements relating to future results of operations, financial condition, business prospects, plans and objectives, are based on the current beliefs, assumptions, expectations, estimates, and projections of the management of Dishman about the business, industry and markets in which Dishman operates. SAFE HARBOR These statements are not guarantees of future performance, and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond Dishman’s STATEMENT control and difficult to predict, that could cause actual results, performance or achievements to differ materially from those in the forward-looking statements. Such statements are not, and should not be construed, as a representation as to future performance or achievements of Dishman. In particular, such statements should not be regarded as a projection of future performance of Dishman. It should be noted that the actual performance or achievements of Dishman may vary significantly from such statements. 23 32 4 Solving Complex Problems for 250+ Multi-Purpose MANUFACTURING RESEARCH & DEVELOPMENT Successful IN-ORGANIC Clients FACILITIES Globally and HIPO LABS GROWTH TRANSACTIONS DISHMAN IN Global Health Authorities CHF 89 M 2,200+ Team Strength decades Committed Members Embracing Approved & Recognized by our Culture of Innovation & A NUTSHELL of Long-Standing Track Record in NEW PRODUCT Sustainability DEVELOPMENT PIPELINE CDMO USFDA, MEB, SWISS MEDIC, Dedicated Team/Scientist Working SPECIALTIES, QUATS & ANSM, WHO, MFDS, PMDA, in R&D - 950+ GENERICS NMPA, EDQM 50% of Technical Staff holding Ph.D 1 Tech Transfer 13 29 Operations in 2 Molecules from Switzerland to oncology therapy entered India, Switzerland, UK, India signed, France, China and the Total Late Phase III Late Phase 3 ongoing Commercialized Netherlands III molecules Molecules Revenue from Operations (₹ mn) EBITDA (₹ mn) and EBITDA % EBITDA EBITDA % 19.3% 17.3% 15.5% 14.3% 13.8% 11.0% 0 7 9 8 5 9 HISTORICAL 2 0 2 5 1 1 3 4 2 5 0 6 1 4 1 1 1 3 4 1 2 6 9 5 7 3 3 8 6 6 Strong basket of 13 molecules 1 2 2 2 2 2 ,2 ,3 ,3 ,2 ,4 ,5 in Late Phase III development. PERFORMANCE FY21 FY22 FY23 FY24 FY25 FY26 FY21 FY22 FY23 FY24 FY25 FY26 Focused on improving capacity utilization by targeting small AT A GLANCE CDMO (₹ mn) Marketable Molecules (₹ mn) and mid-sized global biotech companies and diversifying across new geographies. 4 3 3 0 0 3 2 9 5 8 3 1 6 4 6 9 5 6 3 4 4 6 9 4 9 1 7 7 8 0 , 4 , 6 , 9 , 1 , 2 , 4 7 9 6 4 1 9 1 1 1 2 2 2 ,4 ,4 ,4 ,4 ,4 ,4 FY21 FY22 FY23 FY24 FY25 FY26 FY21 FY22 FY23 FY24 FY25 FY26 AGENDA 01 02 03 Quarter Company Industry Highlights Overview Overview 02 03 Quarter Company Industry Highlights Overview Overview NET REVENUE (₹ mn) EBITDA (₹ mn) & EBITDA MARGIN (%) 19.9% 21.0% 19.0% 17.0% 15.0% 8.9% 13.0% 11.0% 9.0% 7.0% 7,081 6,776 1,407 601 5.0% 3.0% 1.0% Q1FY26 Q1FY27 Q1FY26 Q1FY27 Q1FY27 RESULT HIGHLIGHTS SEGMENT WISE REVENUE BREAKUP (₹ mn) 1,433 6,113 5,344 Q1FY26 Q1FY27 CDMO Marketable Molecules Particulars (₹ mn) Q1 FY27 Q1 FY26 YoY % Income from Operations (Net) 6,776.4 7,080.5 -4.3% COGS 1,142.3 980.9 16.5% Employee Expenses 3,891.0 3,519.0 10.6% Other Expenses 1,142.3 1,173.8 -2.7% EBITDA 600.8 1,406.8 -57.3% EBIDTA Margin % 8.9% 19.9% CONSOLIDATED Other Income 181.6 247.5 -26.6% Depreciation & Amortization 906.8 813.5 11.5% P&L STATEMENT Finance Cost (Incl. Forex Impact) 370.9 427.6 -13.3% Exceptional Items (16.9) (26.5) -36.2% Profit Before Tax (512.2) 386.7 -232.5% Tax Expense 66.6 152.6 Profit After Tax (578.8) 234.1 -347.2% PAT Margin % -8.5% 3.3% Revenue (₹ mn) Q1 FY27 Q1 FY26 FY26 FY25 CDMO 5,343.8 6,112.5 24,412.5 22,930.0 Marketable Molecules 1,432.6 968.0 4,906.5 4,185.0 Total Revenue 6,776.4 7,080.5 29,319.0 27,115.0 REVENUE Total Operating Revenue – Q1 FY27 Total Operating Revenue – FY26 BREAKUP ANALYSIS & CDMO FY26 Q1 FY27 MARGIN Marketable Molecules BREAKUP 79% 83% ANALYSIS EBITDA Margin % Q1 FY27 Q1 FY26 FY26 FY25 CDMO 6.3% 17.9% 19.4% 18.9% Marketable Molecules 18.6% 32.4% 18.8% 9.4% ➢ Net revenue stood at ₹6,776 million in Q1 FY27, down 4.29% from ₹7,080 million in Q1 FY26. The decline was primarily driven by deferment of CDMO revenue, partly offset by growth in the Marketable Molecules (MM) segment. ➢ CDMO revenue declined by 12.6% YoY, primarily due to the customer-requested rescheduling of project deliverables worth approximately CHF 10 million to second half of the financial year. ➢ Revenue from the Marketable Molecules (MM) segment increased by 48% in Q1 FY27 compared with Q1 FY26, primarily driven by higher Cholesterol revenue. Q1FY27 RESULT ➢ EBITDA margin stood at 8.9% in Q1 FY27, compared with 19.9% in Q1 FY26, primarily due HIGHLIGHTS ➢ CDMO segment margin declined to 6.3% in Q1 FY27 from 17.9% in Q1 FY26, due to deferment of CDMO revenues, while the cost base is largely fixed. Additionally, there was a notional foreign exchange loss of INR 117.3 million impacting the margins. ➢ MM segment margin declined to 18.6% in Q1 FY27 from 32.4% in Q1 FY26, primarily driven by higher sales of Cholesterol compared to Vitamin D Analogues. However, these margins are in line with full year FY26 margins. ➢ Addition in Capex during the Q1 FY27 was CHF 4.9 mn. ➢ Net debt excluding lease liabilities CHF 153.6 mn as on June 30, 2026 as compared to CHF 146.8 mn as on March 31, 2026. * The closing CHF/INR exchange rate has been used to calculate net debt in CHF for the respective years. Company Industry Quarter Overview Overview Highlights Established in 1983, Dishman Carbogen Amcis Limited is a fully integrated CDMO (Contract Development and Manufacturing Organisation) company with strong capabilities right from process research & development to late stage clinical and commercial manufacturing and supply of API to innovator pharmaceutical companies. The Company has global presence with development and manufacturing sites in ABOUT US Switzerland, UK, France, Netherlands, India and China. Dishman provides end-to-end integrated high-value niche CDMO offering and has comprehensive product offerings which include APIs, High Potent APIs, Intermediates, Phase Transfer Catalysts, Vitamin D Analogues, Cholesterol, Lanolin-related products, Antiseptic and Disinfectant formulations. Global integrated CDMO End-to-end capabilities with bi-continental under one roof — manufacturing footprint spanning pre-clinical for complex, high-value KEY development, process molecules. optimization, scale-up, STRENGTHS STRENGTHS and global commercial manufacturing. Strong integr [Showing first 8,000 characters — download PDF for full document]